Effect of Prostaglandins on the Regulation of Tumor Growth
| Autor: | Shunji Ishihara, Toshihiko Okuyama, M. A. K. Rumi, Yoshikazu Kinoshita |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
musculoskeletal diseases
Cyclopentenone endocrine system Cancer Research Receptors Cytoplasmic and Nuclear Peroxisome proliferator-activated receptor Antineoplastic Agents Apoptosis Growth inhibitory medicine.disease_cause chemistry.chemical_compound Neoplasms medicine Animals Humans Tumor growth Receptor Pharmacology chemistry.chemical_classification urogenital system Cell Cycle In vitro Cell biology ErbB Receptors Gene Expression Regulation Neoplastic carbohydrates (lipids) chemistry Cancer cell Prostaglandins Molecular Medicine lipids (amino acids peptides and proteins) Carcinogenesis |
| Zdroj: | Current Medicinal Chemistry-Anti-Cancer Agents. 4:379-387 |
| ISSN: | 1568-0118 |
| Popis: | Prostaglandins (PGs) are involved in mediating or regulating many physiological as well as pathological processes. Important roles of PGs in the pathophysiology of carcinogenesis offer potentials of targeting PG synthesis and PG receptors in developing novel anti-cancer therapy. Although initial studies suggested direct growth inhibitory role of PGs from in vitro studies, it has been widely demonstrated that in general, PGs stimulate tumor growth. However, cyclopentenone PGs, especially 15d-PGJ2, which can activate peroxisome proliferator activated receptor (PPAR) gamma, exhibited anti-proliferative and proapoptotic effects on many types of cancer cells. But recent studies indicate that growth inhibitory effects of the cyclopentenone PGs might also be a nonspecific effect due to its highly reactive cyclopentenone ring. We have explored the published studies on PGs to specify its known regulatory roles on tumor growth with an objective of targeting the PGs or pathways activated by these lipids in treating cancers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|